NSAIDs and the elderly. Toxicity and economic implications

Drugs and Aging

Volumn 10, Issue 2, 1997, Pages 119-130

  Phillips, Andrée C ^a,b   Polisson, Richard P ^a,b   Simon, Lee S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; TRAMADOL;

AGED; BLOOD TOXICITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MONITORING; GASTROINTESTINAL SYMPTOM; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SKIN TOXICITY; STOMACH PROTECTION; TOXICITY;

EID: 0031058680     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710020-00005     Document Type: Review

References (62)

1. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990; 263: 2335-40
2. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686-92
3. Furst DE. Are there significant differences among nonsteroidal anti-inflammatory drugs? Arthritis Rheum 1994; 37: 1-9
4. Furst DE, Anderson W. Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1993; 36: 804-10
5. Cush JJ, Lipsky PE, Postlethwaite AE, et al. Correlation of serologic indicators of inflammation with effectiveness of non-steroidal antiinflammatory therapy in rheumatoid arthritis. Arihritis Rheum 1990; 33: 18-28
6. Cush JJ, Jasin HE, Johnson R, et al. Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum 1990; 33: 623-33
7. Hammerman D. Clinical implications of osteoarthritis and ageing. Ann Rheum Dis 1994; 30: 82-5
8. Flynn B. Rheumatoid arthritis and osteoarthritis. Current and future therapies. Am Pharm 1994; NS34: 31-42
9. Murray MD, Brater DC. Nonsteroidal anti-inflammatory drugs. Clin Geriatr Med 1990; 6: 365-441
10. Dieppe PA, Frankel SJ, Toth B. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet 1993 Feb 6; 341: 353-4
11. Oddis CV. New perspectives on osteoarthritis. Am J Med 1996; 100 Suppl. 2A: 10S-5S
12. Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19: 1950-4
13. Langmen MJS. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 1988; 84 Suppl. 2A: 15-9
14. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996; 124: 577-84
15. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammaiory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory-induced damage. Arch Intern Med 1992; 152: 1145-55
16. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984; 13: 120-3
17. Hochberg MC. Association of nonsteroidal unti-inflammatory drugs with gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992; 19: 63-7
18. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96
19. Miller DK, Burton FR, Burton MS, et al. Acute upper gastrointestinal bleeding in elderly persons. J Am Geriatr Soc 1991; 39: 409-22
20. Elashoff JD, Grossman MI. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978. Gastroenterology 1980; 78: 280-5
21. WHO. World health statistics annual 1985. Geneva: WHO, 1985
22. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63
23. Freston MS, Freston JW. Peptic ulcers in the elderly: unique features and management. Geriatrics 1990; 45: 39-42
24. Permutt RP, Cello JP. Duodenal ulcer disease in the hospitalized elderly patient. Dig Dis Sci 1982; 27: 1-6
25. Simon LS. Toxicities of the nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1992; 4: 301-8
26. Simon LS, Basch CM, Young DY. Effects of naproxen on renal function in older patients with mild to moderate renal dysfunction. Br J Rheumatol 1992; 31: 563-72
27. Murray MD, Black PK, Kuzinik DD, et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995; 310: 188-7
28. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 228-35
29. Paulus HE. FDA Arthritis Advisory Committee meeting. Arthritis Rheum 1982; 25: 1124-5
30. Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut 1991; 32: 1381-5
31. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25: 1013-5
32. Saag KG, Rubenstein LM, Chrischilles EA, et al. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995; 22: 2142-7
33. Inman WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. BMJ 1977; 1: 1500-5
34. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87-91
35. Jones AC, Berman P, Doherty M. Nonsteroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. BMJ 1992; 31: 45-8
36. Bombardier C, Peloso PMJ, Goldsmith CH. Salsalate, a non-acetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 617-24
37. Blechman WJ, Lechner BL. Clinical comparative evaluation of choline magnesium trisalicylate and acetylsalicylate in rheumatoid arthritis. Rheumatol Rehabil 1979; 18: 119-24
38. The Multicenter Study Group. Trial of non-acetylated salicylate in RA: does the acetyl group contribute to the antiinflammatory efficacy of salicylic acid in treatment of rheumatoid arthritis? J Rheumatol 1989; 16: 321-7
39. Townsend RJ. Post-marketing drug research and development. Drug Intell Clin Pharm 1987; 21: 134-6
40. Bootman JL, Townsend RJ, McGhan WF, et al. Principles of pharmacoeconomics. Cincinnati (OH): Harvey Whitney Books Company, 1991
41. Accunet Version 6.0. 1996 Mar 11
42. Greene JM, Winickoff RN. Cost-conscious prescribing of non-steroidal anti-inflammatory drugs for adults with arthritis. Arch Intern Med 1992; 152: 1995-2002
43. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 1019-22
44. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84 Suppl. 2A: 20-4
45. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40: 1345-50
46. Simon LS, Hind HT, Bittman RM, et al. Risk factors for serious NSAID-induced GI complications: regression analysis of the MUCOSA trial. Fam Med 1996; 28: 202-8
47. Hogan DB, Campbell NRC, Crutcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994; 151: 315-22
48. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-62
49. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 214-49
50. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-59
51. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639-46
52. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 1990; 38: 187-99
53. De Pouvourville G, Bader JP. Analyse économique du traitement préventif par le misoprostol chez l'homme des ulcères gastriques liés aux anti-inflammatoires non stéroïdiens. Gastroenterol Clin Biol 1991; 15: 399-404
54. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264: 41-7
55. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
56. Maetzel A, Ferraz MB, Bombardier C. A new examination of the cost-effectiveness of misoprostol in preventing serious gastrointestinal bleeding due to NSAIDs [abstract]. Arthritis Rheum 1995; 38 Suppl.: S206
57. Gabriel SE, Campion ME, O'Fallon WM. A cost utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 333-41
58. De Pouvourville G. Pharmacoeconomics of the prevention of NSAID-induced ulcers and their complications. N Standards Arthritis Care 1996; 5: 7-10
59. Centers for Disease Control and Prevention. Arthritis prevalence and activity limitations: United States. MMWR Morb Mortal Wkly Rep 1990; 43: 433-8
60. French MT, Mauskopf JA. A quality-of-life method for estimating the value of avoided morbidity. Am J Public Health 1992; 82: 1553-5
61. Devellis BM. Depression in rheumatological diseases. Baillieres Clin Rheumatol 1993; 7: 241-57
62. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 122: 61-70